King of Prussia, Pennsylvania 19406


Purpose:

Double-blind, randomized, multicenter, placebo-controlled study The purpose of this study is to evaluate the efficacy and safety of HMPL-004 in patients with active moderate Crohn's Disease,compared with placebo.


Criteria:

Inclusion Criteria: - Have active confirmed Crohn's Disease (confirmed radiographically, endoscopic, or histologically), with a CDAI of 220-400 at baseline screen Exclusion Criteria: - They have received anti-TNF-α antibody within 3 months of starting study medication, or cyclosporine, tacrolimus, thalidomide or mycophenolate mofetil within 2 months of starting study medication


NCT ID:

NCT00655733


Primary Contact:

Xiaowei Lu, MD
Phone: 973-325-5668
Email: Xiaowei.Lu@OmnicareCR.com


Backup Contact:

N/A


Location Contact:

King of Prussia, Pennsylvania 19406
United States

Xiaowei Lu, MD
Phone: 973-325-5668
Email: Xiaowei.Lu@OmnicareCR.com

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.